THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Britta Siegmund 1
Bruce E. Sands 2
Karen Hamrick Samaan 3
Xingyuan Li 3
Nathan Morris 3
Theresa Hunter Gibble 3
Isabel Redondo 4
Trevor Lissoos 4
Geert R. D'Haens 5
1 Charité - Universitätsmedizin Berlin, Berlin, Germany
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Eli Lilly and Company, Indianapolis, United States
4 Eli Lilly and Company, Lisbon, Portugal
5 Amsterdam University Medical Center, Amsterdam, Netherlands
Conference
UEG Week Vienna 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]